

Index

- AAI *see* Accelerating Access Initiative
- Abacavir 31
- Abbott, patents 32
- abolition of pre-grant opposition 57
- absenteeism 306
- ACAME 82
- Accelerating Access Initiative (AAI) 82, 253
- 'ACCESS program' 9–10
- access programmes 59, 80, 97, 101, 120–28
- in SS Africa 227–9
- access to care 21–4
- accreditation 305
- active pharmaceutical ingredients (APIs)
- imports from China and India 127, 155
- adherence 269
- adult population, drugs for 83
- African countries, prices of ARV drugs 78–99
- age groups 182
- Agence Nationale de Recherches sur le Sida et les hépatites virales (ANRS) 45, 98, 110, 277
- agreements, comprehensivity 65–7
- agricultural sector, impact of HIV/AIDS 66, 212
- AIDS associated Retrovirus (ARV) 9, 10
- AIDS programmes, local, Brazil 112–16
- AIDS-related mortality, Brazil 114
- AIDS relief 6–8
- AIDS treatment programme, Senegal 291
- AIDSLINE database 191
- Aluvia® 41
- Angola 217–20
- anonymity because of stigma 264
- ANRS *see* Agence Nationale de Recherches sur le Sida et les hépatites virales
- antenatal clinics (ANC) 176–7, 263
- HIV prevalence 178–81
- antibiotics 275, 293
- anti-fungal agents 292
- anti-inflammatories 275, 293
- antiretroviral therapy (ART) 22, 25–51, 78, 151, 276
- cost-effectiveness evaluation 198
- coverage 80
- efficacy and toxicity 203–4
- prescribers 266
- antiretrovirals 53–4, 121–2, 141
- see also* ARV drugs
- ANVISA grant 138
- API *see* Active Pharmaceutical Ingredients
- Arab countries 61
- Argentina, technical cooperation 125
- ART *see* antiretroviral therapy
- ARV *see* AIDS associated Retrovirus
- ARV drugs 13, 23
- availability 93–6, 225–54
- in Brazil 150–65
- delivery sites 264–6
- market penetration 96
- prices 88–92
- in African countries 78–99
- procurement policies 225–54
- therapies 31, 82
- transactions, data on 79
- treatment, unequal access 26
- ASEAN Initiative (EAI) 56
- Asian generic producers 9, 12
- assessment of applications 5
- Association of South East Asian Nations (ASEAN) 56
- Atripla® 153, 268
- audits, regular 305
- Aurobindo company, India 42, 243

- availability of ARVs, problems 225–6
- avian flu 163
- Azydothymidine (AZT), reverse engineering 136
- Bamako Initiative 299, 300
- banking 66
- Benin 80, 217–20
- Berne convention 55
- bias in surveys 175
- bilateral agreements 52, 54, 55, 71
- bilirubinemia 280
- bioavailability tests 44
- bioequivalence 12, 44
- biological tests 264, 274, 276
- Bio-Manguinhos, Brazil 122
- biomedical research 296
in US 159
- biosafety 150
- blood count 277
cost estimate 276, 280
- branded drugs 86, 88
- brand-name producers 121
- brands versus generics 93–5
- Brazil
compulsory licensing 38–44
fight against AIDS 22
free of cost access 15, 33–4
health system 108
pre-grant opposition 37–8
price reduction 9
scaling-up process, success of 105–18, 113–14
technical cooperation 124–6
TRIPS flexibilities 42–4
- Brazilian Association of Fine Chemicals 38
- Brazilian Industrial Property Law 43, 151
- Brazilian Ministry of Health 43
- Brazilian National STD-AIDS programme 151
- Brazilian Patent Office 37, 155
- Brazilian regions, differences 114–16
- Bristol-Myers Squibb (BMS) 87
- budget for fight against AIDS 282–5, 297, 299
- Burkina Faso 80, 226–7, 233
regional trends 183
- buying agencies, central 225, 229–35
Denmark 239
- caesareans, free 292
- calibration 181
- CAMEG, Burkina Faso 233
- Cameroon 217–20, 226–7, 259–71
ART programme 267–8
public health approach 261–3
supply of ARVs 246–7
- Campinas University, Brazil 132–4
- cancer 54
- capacity-building 264–6
- care system for poor 298–300
- Caribbean Basin Initiative 69
- CD4 cell count 191, 203, 270
cost estimate 275, 280
- CD4 lymphocyte counts 292
- CD4+ cell counts 269
- CEME, (government drug agency)
Brazil 134
- CENAME, Cameroon 226, 236–9
drug supply system, Cameroon 267
- Central America Free Trade Area (CAFTA) 56, 61
- Centre Afrique 217–20
- Chembio, American pharmaceuticals firm 122
- chemical engineering 132
- chest X-ray 276–7
- childbirth 292
right to coverage costs 275
- children, free treatment 267
- Chile 56
- cholesterolemia 280
- Cipla, Indian generic producer 9, 10, 42, 87
- cities, vulnerability 184
- civil society, 62–4, 107–8
- clinical-immune status, cost estimate 280
- clinical trials 268–9
- Clinton Foundation 42, 262, 267
- clopidogrel bisulfate, heart disease drug 47
- Codetec 131–5
- Combid® 40
- community
financing schemes 301
involvement 260, 264
relay workers 266

- competition and price reductions 23
 compulsory licences 33, 38–44, 143–5, 150–65
 of ARV, Brazil 156–8
 of Kaletra 157
 computable general equilibrium (CGE) model 214–20
 condoms 126
 increase in use 114
 consultation fees 274, 275
 contraceptive methods 176
 contract law in transfer agreements 125–7
 contractualization 302, 306
 cooperation between developing countries 123
 copying drugs 131, 136–40
 corruption 239
 cost effectiveness
 of ART therapies 190–209
 research agenda 208–9
 Costa Rica
 complaints to court 63
 FTA referendum 69
 costs
 ARV drugs 110
 calculation for medical treatment 275–8
 minimization 261
 reimbursement by state 302
 Côte d'Ivoire 217–20
 co-trimoxazole 201, 276, 292
 counselling, confidential 264
 Country Coordinating Mechanisms (CCMs) 4, 5
 court ruling on Efavirenz 144–5
 coverage rates 228
 creatine, costs 276–7
 Cristalia 44, 142, 144
 Cuba, technical cooperation 125
 cultural obstacles in horizontal transfer 127

 data collection 82–3
 deaths from AIDS 1, 27
 decentralization
 of ART, Cameroon 270
 of ISAARV 305
 Decentralization Allocation Fund 297

 decentralization process 263–7, 275
 defined daily doses (DDDs) 83
 Demographic and Health Surveys 170, 177
 developing countries
 IPR constraints 151
 technical cooperation between 123–5
 TRIPS compliance 151
 diagnostic tests 126–7
 Didanosine (ddI) 31, 85, 91
 DISC project (USAID) 306
 discrimination against HIV-infected 115, 264, 266
 distribution system 237
 district health centres 293
 district level funding 297
 doctors and pharmacists 80, 259
 Doha Declaration 53, 57, 59, 72
 Dominican Republic 56
 donors
 to health structures 295, 300–301
 pledges 7
 dosage regime 37
 drug procurement 267
 institution, CENAME 262
 policy in Cameroon 236–9
 drugs
 copying
 in Brazil 130–48
 prohibition 120
 costs, Thailand 39
 evaluation 11
 marketing approval 52, 57
 patent constraints 13–14
 prequalification 10–13
 price reduction 79, 121
 supply 14, 260
 treatment evaluation 277

 education sector, impact of HIV/AIDS 212
 Efavirenz (EFV), drug 30–33, 38, 40
 Brazil 42–44, 156
 compulsory license dispute 158–60
 prices 91
 Efavirenz case 142–5
 employer health insurance 301
 Endogenous Growth CGE model 217–20
 entry points expansion 263

- Epidemic Projection Package (EPP) 170
- epidemics
 overestimation 170
 sickness 70
- epidemiological data 80, 198
- epidemiological situation, Senegal 274–5
- Epidemiology Reference Group 170
- EpiModel 170
- equipment donations funding 296
- equity
 funds 303
 in scaling-up 261
 in treatment 266–7
- ESTHER project, France 262, 265, 268
- estimates
 of care costs 278
 of treatment demand 278
- exchange and cooperation 140–42
- exemption status 298
- external dependence, for drugs 241
- external funding 239–40, 251–2
- Fann Hospital (CRCF) 294, 307
- Far Manguinhos federal laboratory,
 Brazil 37–44, 122, 135, 140
 dispute with Merck 143–5
 Nigeria and 125
 subsidiary, Mozambique 125–6
 Zambia and 125
 Zimbabwe and 125
- Fast-Track procedure 13
- FDA *see* Food and Drug Administration
- FDCs *see* fixed-dose combinations
- federal aid, Brazil 111
- Federal University of Rio de Janeiro 142
- female population, Africa 176
- fertility in women 176
- fiduciary funds 305
- financial incentives for HIV/AIDS programmes 111
- financial resources 2–8, 227–8
 Brazil 109, 116–17
- first-line strategy 268
- first-line to second-line treatment 79, 86–7, 92, 191
- fixed dose combinations (FDCs) 10, 37, 96, 268
- flow cytometers 296
- Food and Drug Administration (FDA)
 approved drugs 8, 12, 13
 qualification for generics 13
 Thailand 41
- Ford Foundation 110
- foreign suppliers of drugs, Cameroon 236
- free access 255–7
 cost assessment 284
- free childbirth 292, 294
- free distribution of ARVs 130
- free drugs and free care 288, 291
- Free Trade Agreement (FTA) 22, 52–74
 comprehensive 66
 mobilization against 68
 negotiations 59–69
- Free Trade Area of the Americas (FTAA) 56
- French price project (ETAPSUD) 79, 80–93
- French-speaking African countries 225–54
- Fumaric Acid 36
- fund commitments in advance 5
- funding
 donor agencies 79
 eligibility for 262
 modalities for free access 291–310
 nature and origin of 251
 supplying products 294
 types of 294–304
- fundraising 306–7
- G8 summit, Gleneagles 1
- Gabon 80, 228
- General Agreement on Tariffs and Trade (GATT) 55
- general antiretroviral drugs, import 54, 261
- generic competition 30, 95
- generic drugs 11, 12, 21–7, 86–8, 126
- international market 34
 prices 236, 237
 producers 121
 synthesis routes 139
 Thailand 38

- generic pharmaceutical companies 10, 12
 - cooperation 123–4
 - India, Efavirenz 31–2, 35
 - prioritization 225
- generics-oriented model 245–8, 251
- genetic engineering 150
- genotype resistance testing 204
- Gilead Sciences Inc.
 - patent application 35–7, 47
- Glaxo's Azydothymidine (AZT) 136
- GlaxoSmithKline (GSK) 87, 243
- Glivec case 47
- Global Fund against Tuberculosis, AIDS and Malaria (GFTAM) 3–7, 79, 262, 265
- Global Price Reporting Mechanism (GPRM) 79
- global transfer trend 122
- glucosemia 276–7
- 'gold standard' approach treatment 270
- governance models 227, 229–36, 251
- governance systems and ARV
 - availability 240–50
- government initiatives, Brazil 152
- Government Pharmaceutical Association, Thailand 39
- grant portfolio 6
- Guinea low-resource country 239–40
 - Market 249–50
 - mixed model 248
 - speciality model 242
- Guinea-Conakry 226–7
- HAART *see* highly active antiretroviral therapy
- harm reduction policy, São Paulo 107
- HBV-HCB serology 277
- health centres, revenues 300
- health issues, marginalised 66–8
- Health Ministry, Brazil, loan 134
- health and trade policy 67, 70
- healthcare
 - constraints on 97
 - demand and consumption 215–17
 - resources 208
 - training 262
- hepatitis 54
- herpes virus infections 277
- Hetero Drugs, generic company, India 41
- high risk groups 183
- highly active antiretroviral therapy (HAART) 42, 105, 114, 270
- HIV/AIDS
 - coordinating body 3
 - data sources 174–5
 - epidemics 44
 - Brazil 105
 - funding, rise in 190
 - infection spreading 202
 - prevalence
 - African countries 171–6, 180
 - by socio-demographic characteristics 182–4
 - in women, underestimation 176
 - serostatus 266
 - surveillance, Sub-Saharan Africa 169–76
 - testing 292
 - kits, transfer agreement 122–3
 - therapy, expanded access 33
 - universal free access 83–4, 273–89
- HIV ART, cost effectiveness 192–7
- HIV counselling 262
- HIV-infected populations 80
- HIV-resistant strains 269
- homosexuals 116, 183
- horizontal cooperation 123–8
- hospitalization costs 274, 277
- hospitals
 - funding 298
 - services 264
- human capital and economic growth 213
- human right, medical drugs as 110
- hybrid strategy 201, 202
- hypersensitivity syndrome 269
- ideology of agreements, FTAs 64
- immunological tests 264
- importation of raw material 143
- imports of drugs, Cameroon 236
- improvement in drugs 131
- incentivos* policy, Brazil 110–11
- India 126
 - analysis for cost-effectiveness 200, 206–7
 - fight against AIDS 22

- generic supplier 13, 245
- 'pharmacy of Third World' 9
- raw material from 143
- technical experience 34
- Tenofovir case 35–7
- Indian Patent Law 37
- Indinavir (IDV) 85, 91, 122
- industrial knowledge 130–48
 - in Brazil 130–48
- inequality 61–2
- infections
 - decreased 222
 - diseases and poverty 151
 - increase in poor in Brazil 105
 - opportunistic 276
- injection drug users 107
- innovation standard 35–6, 131
- intellectual property (IP) 14
 - of drugs 22, 37
 - flexibilization 25–51
 - impact, post-2005 28–9
 - international agreements 14
 - laws, threats, changes 245
 - Brazil 154–6
 - protection 52–74
 - regulation 34, 35, 251, 252
 - US experience of 62
- Intellectual Property Rights (IPR) 60, 61, 97, 150
 - constraints 163–4
- international AIDS agencies, rigidity 271
- international charities 120, 252
- international donors 240, 305
- international law and IP 120
- international non-proprietary names (INNs) 82
- intramolecular versus intermolecular competition 95–6
- investment funding 296
- invitation to tender 296
- invoice targeting 300
- iron 275, 293
- ISAARV programme, Senegal 277
- IST/AIDS programme, Brazil 109

- Kaletra® 40, 41, 157
- Kaposi's sarcoma 277
- knowledge accumulation 139–40, 163

- Labogen laboratory, Brazil 134–5, 144
- laboratories
 - equipment donation 296
 - infrastructures 259
 - marketing authorization 249–50
 - reverse engineering 132–5
- Lamivudine (3TC) 84
- Laos 56
- Latin American countries 61
- legal changes 120
- legal dispute with Merck over
 - Efavirenz 143–5
- legal status of buying groups 234
- leprosy, right to coverage costs 275
- less developed countries (LDCs) 212–23
- life expectancy, increased 222
- life-saving cost 191
- Local Fund Agents (LFAs) 4
- local knowledge 131
- local supplies 236
- Lopinavir/Ritonavir 31–3, 156, 38
- loss compensation 296
- low-income countries 31, 32, 255–7

- macroeconomic development 213
- macroeconomic estimates 271
- macro-modelling, research limitations 220–22
- malaria 4
- Mali 80, 226–7
 - mixed model 248
- management independence 230
- Management Units (MUs) 264, 265
- market for ARVs 27–8
- market competition 86–7, 93–6
- market mechanisms 79
- market shares 87–8, 95
- marketing approval
 - exclusive rights 57
 - refusal 57
- Markov state-transition model 200
- mathematical modelling 199, 207
- Matrix, Indian pharmaceutical company 30, 41
- Médecins Sans Frontières (MSF) 10, 27, 29, 42
- median price 31
- medical appointments missed 266

- medical care
 - costs 281, 285
 - for PLWHA 291–310
- medical coverage, Senegalese law 301
- medical databases 106
- medical imaging costs 275–6
- medical treatment, estimated demand 279
- medication availability 9–13, 120
- medicines
 - in developing countries, access 52
 - market 27
- Medline database 191
- mentor supervising 264, 265
- Merck & Co. (MSD) 42, 87
 - compulsory license dispute 158–60
 - pharmaceuticals 110
 - pricing policies 31
- Microbiologica, Rio de Janeiro 133–4
- micro-credit 305
- Middle East Free Trade Area (MEFTA) 56
- middle-income countries 252
- mining industry, impact of HIV/AIDS 212
- Ministry of Health, Hygiene and Prevention, budget 283
- mixed model 248–51
- molecular biology 150
- molecules, patentability of 21, 22
- monetary costs 191
- monitoring strategies
 - cost-effectiveness 203, 204, 276
 - and evaluation system 263
- monotherapy 204
- Moroccan agreement 60, 61, 72
- Morocco 58
 - health institutions 66
 - textile productions 74
- mortality 270, 286
- mother-to-child transmission (MTCT) 114, 116, 206, 263
- Mozambique 217–20
 - technical cooperation 125
- MSF *see* Médecins Sans Frontières
- MU *see* Management Unit 264, 265
- Multi Country AIDS Programme (MAP) 3, 4
- multinational funding 235
- multinational pharmaceutical companies 158–60
- mutual aid projects 301
- National AIDS control programmes (PNLS) 82, 225
- National AIDS Council (NAC) 3
- National Council for Fight against AIDS (CNLS) 293
- national drug regulation agencies (NDRAs) 30
- National Essential Drug List 39
- National Health Security System, Thailand 39
- national income (GDP), reduction 213
- national leader's role, FTAs 64
- National Strategic Plan budget 286, 287
- National Supply Pharmacy, Senegal 284, 294
- needle-exchange programme 107
- negotiating 60–62
- Nelfinavir, Brazil 156
- Nevirapine (NVP) 30
 - prices 89, 90, 91
- non-governmental organizations (NGOs) 60
 - network, federal level, Brazil 106, 111–12
 - supply of ARVs 248
 - support from World Bank 110
- non-nucleoside reverse transcriptase inhibitor (NNRTI) 83, 85, 87, 268–9
- non-response to surveys 170, 182
- Nortec laboratory 135, 144
 - cooperation 141, 142
- Nortec Quimica, Brazil 44
- North American Free Trade Association (NAFTA) 55
- nucleoside reverse transcriptase inhibitor (NRTI) 83, 85, 269
- observational cohorts 198
- old people 292
- operational research 271
- opportunistic infections 280
- Organisation Africaine de la Propriété Intellectuelle (OAPI) 82
- originator ARVs 86
- orphaned children, care for 284

- pandemic of HIV/AIDS 152
- Paraguay, technical cooperation 125
- parallel imports, prohibition 57
- Paris Accord 2005 302
- Paris convention 55
- Patent Act 1970, India, amendment 35–6
- patent holders, cooperation 131
- patent justification 21
- Patent Office (PTO), India 32, 36
- patent protection 30, 52, 82, 93, 94
- patentability of pharmaceuticals 120
- patented drugs 8, 240–45
 - copying 120
 - distribution 9–10
- patented inventions 27
- patents
 - for antiretrovirals 122
 - applications, potential contestations 34
 - breaking, Brazil 110
 - disadvantages of working from 136–7
 - enforcement 93–5
 - granting 155
 - international 136–7
 - power struggles 142–5
- patients treated with ARV drugs, costs 280
- payment mechanisms in developing countries 97
- People Living With HIV/AIDS (PLWHA) 1, 2, 271
 - association members 274
- Pepfar 6–8, 11
- performance aid funds 303
- performance-related systems 306
- Peru presidential election 69
- Peruvian Nationalist Party (PNP) 69
- pharmaceutical companies 9, 10
 - brand images 94
 - Brazil 151
 - large 252
- pharmaceutical laboratories 127
 - Brazil 132–5
- Pharmaceutical Manufacturers Association, South Africa 94
- pharmaceutical patent protection, Africa 94
- pharmaceutical policy 239
- pharmaceutical production capacity 79
 - patenting of 26, 150
- pharmaceutical R&D, alliances 163
- Pharmacquick 87
- pipeline provision for drugs 155
- plasma HIV RNA 268–9
- Plavix® 41, 47
- PLWHA *see* People Living With HIV/AIDS
- PNLS *see* Power of National AIDS Control Programmes
- political authorities, lack of support 115
- political and economic matters, predominance 66–7
- poor people 292
 - neglect of, in Brazil 115–16
- population-based surveys 175, 177–84
- populations, and infectious diseases 151–3
- poverty 206
- Power of National AIDS Control Programmes (PNLS) 233
- power relations, unequal 67
- 'preferential prices' fixed by company 10
- pregnant women
 - HIV screening 114
 - Senegal 274
- pre-grant opposition 34–8
- prequalification system 12, 13
- President's Emergency Plan for AIDS Relief (Pepfar) *see* Pepfar
- price comparisons of drugs 28
- price index 83, 215
- price project, ETAPSUD 80
- prices 59, 82
 - evolution of 89–92
 - of medications 8–13, 33, 54, 152–3, 163
 - reductions 9, 261
 - of generic drugs 95
 - in Thailand 34
 - stabilization 89
 - subsidies 274
 - variations 9–10, 12, 31–2
- primary health-care system 260
- Principal Recipients (PR) 4
- private wholesalers 237–8, 248

- privileged relations with USA, FTAs 65
 procurement policies 238
 production capacity, Brazil 153–6
 production, local 120, 130
 prophylactic medications 201
 protease inhibitor (PI) 31, 83, 269
 protection levels 55, 58–9
 protein inhibitors 134
 prothrombin 28
 provincial drug procurement centres, CENAME 236–7
 psychological support workers 265
 public authorities, relations with 251
 public commercial establishment (EPIC) 234–5
 public health 59, 66
 approach
 to ART 259–71
 in Brazil 106
 in Cameroon 261–3
 US trade policy 69, 70
 public health systems 8, 109, 255–7
 public healthcare services 292
 public institution, funding of 298
 public protests against FTAs 69
 purchasing fund system 291–310
 for PLWHA 302–8
 purification of molecules 138

 qualification process 8
 quality control laboratory, national 262
 quality standards 10, 13
 quantities and prices 79

 R&D Credit Coalition 159–60
 R&D funds 162
 Ranbaxy, India 40, 42
 raw materials 126, 130
 regional agreements 54
 regional hospitals 299
 regulatory procedures 150
 renal function 269
 Republic of Congo 80
 resistance to ART 269
 resources
 limitation 190–209
 mobilization 109–11
 restrictions on buying 240–50

 reverse engineering 138–42
 Brazil 130–48
 power struggles 142–5
 risk of new medications 159
 Ritonavir, protease inhibitor 31, 83
 Roche, pharmaceuticals 110
 rural areas, vulnerability 184

 safety standards 12, 13
 safety of strategies 260
 salinization process 38
 salt (desoproxil fumarate) 38
 sanitariat movement 108
 sanitary surveillance agencies (ANVISA) 44
 São Paulo, Brazil, AIDS cases 107
 scaling-up
 ART 215–20, 259
 Brazil 109–13
 HIV treatment 255, 260, 261
 objective 26–32
 screening programme 271
 screening tests 275
 second-line ART, use of 199–202
 second-line ARVs, Brazil 101
 second-line and first-line regimens 84
 secrecy of negotiations 62–4
 Senegal 80, 226–7
 ARVs in 243, 244
 fight against AIDS 282–4
 free access to drugs 273–89
 law, employee medical coverage 301
 patented drugs 240–45
 Senegalese system, history 292–4
 serology, HNV-HCB, costs 276
 seropositive people, estimated numbers 279
 seroprevalence surveys 169
 Sesame Plan 298, 301
 sex workers 274
 exclusion 158
 vulnerable groups 115–16
 sexual behaviour 182
 Sexually Transmitted Disease (STD) clinics 263
 Sidaction, French research sponsor 226
 simplified approach treatment 270
 Singapore 56, 198
 social discrimination 115, 116
 social security system 70, 80, 287

- social surveys of patients 298
- sources of funding for drugs 283
- South Africa 126, 200, 208
- South Korea, objections 63–4
- spatial variations of HIV prevalence 183–4
- speciality drugs, patented 239
- speciality imports 236
- speciality-oriented model 240–45, 251
- stability tests 44
- standard care packages 260
- state representation 305
- statistical analyses 82–3
- Stavudine (d4T) 84, 139
 - standard molecules 137–8
- stigma 266
- Sub-Saharan Africa 1, 15, 26, 78, 120
 - HIV prevalence in 169–85
 - market competition 93–6
- subsidies 292, 196
- subsidizing funds 303, 304
- supply policy 82
- support from country 260
- survival benefit 208
- SYNAME, drug supply system,
 - Cameroon 262, 264, 267
- synthesis of molecules 138–40
- synthesis technologies of Efavirenz 144–5

- target groups 82
- tax credits 161
- technical cooperation, international
 - centre, Brazil 124–6
- Technical Review Panel (TRP) 4, 5
- technical support 111
 - for Cameroon 263
- technical training for test-kit
 - construction 122
- technological cooperation on AIDS 126
- technological knowledge distributor 142
- technological sophistication, Africa 296
- technology transfer 121–3
 - agreements, Brazil 120–28
 - in pharmaceuticals 125, 126
 - through voluntary licences 130
- telecommunications 66

- Tenofovir Disproxil 36
- Tenofovir (TDF), first-line regimen 29–30, 33
 - Brazil 156
 - India 35–7
 - patent application, opposition 34–8
- textile industry, Morocco 67
- Thai Senate Foreign Affairs
 - Committee 63
- Thailand
 - analysis for cost-effectiveness 205–6
 - compulsory licensing 38
 - fight against AIDS 22
 - general retroviral drugs 34
 - NGO coalitions 63
 - policy, reactions to 41
 - technical cooperation 125
- therapeutics 268–9
 - combinations, Senegal 282
 - prices 92
- third party, reimbursement by 300–02
- Third World countries,
 - interdependence 123
- threat to AIDS control programmes 26
- trade
 - arrangements, US 67, 68
 - negotiations 59–67
 - preferences 69
 - sanctions, US threats 154
- Trade Promotion Authority (TPA) 55
- Trade-Related Intellectual Property
 - Section (TRIPS) 13, 52
- training 260
- transfer agreements, horizontal
 - technology 125
- treatment centres 262
- treatment costs
 - changes in 280
 - rising, Brazil 117
 - in Sub-Saharan Africa 78
- treatment interruption 269
- treatment of patients 255
- treatment and prevention 110
- triglyceride 280
- TRIPS agreement 2005 13–14, 21–4, 27, 150
 - compliance, 2005 22, 153–6
 - constraints, post-2005 25–51
 - legal flexibilities 33
 - plus provisions, refusal 60

- tritherapies 1, 9
 - fixed dose, Triomune 9
- tuberculin test costs 276, 277
- tuberculosis 4, 264
 - right to coverage costs 275
- tuberculosis diagnosis and treatment centres (TDTC) 263

- UNAIDS 261
- UNITAID 262
- United Nations Children's Fund (UNICEF) 110
 - and Sub-Saharan Africa 239
- United Nations Conference on Trade and Development (UNCTAD) 55
- United Nations Human Rights Committee 63
- United Nations programmes 235
- United States 55
 - economic superiority 62
 - market access 65–6
 - trade agreement
- United States Agency for International Development 8
- United States Congress 68
- United States free trade policy (FTA) 55, 60, 67–8
- United States Trade Representative (USTR) 60
- universal access to drugs 1, 2, 26, 78, 152
- universal public health system (SUS), Brazil 108–9
- universities, benefits of interaction 135
- Uruguay Round, 1984 54, 150
- USAID *see* United States Agency for International Development

- user charges 256
 - abolition 273
 - for ART 266
 - curtailment 261

- vaccines, innovation need 160–63
- victims of AIDS, care for 284
- Vietnam 56
- viral load testing 203, 267
- viral resistance to ARV drugs 152
- viral suppression 83
- virological response 268, 269

- women in Brazil 105, 115–16
- World Bank
 - authority of 239
 - loans, Brazil 110
- World Bank Multi Country AIDS Program (MAP) 3–4
- World Development Indicators (WDI) 217
- World Health Assembly 2005 126
 - Committee on Intellectual Property (CIPIH) 162
- World Health Organization (WHO) 1, 239, 259, 261
 - guidelines to treatment 83
 - IP rules 53
 - prequalification 10–13
- World Intellectual Property Organization (WIPO) 55, 71, 163–4
- World Trade Organization (WTO) 150
 - standards 59

- Yaoundé central hospital 265

- Zidovudine (AZT) 37, 85
- Ziguinchor Hospital, statistics 299

